Posted by Michael Wonder on 30 Jul 2016
CADTH recommends reimbursement of Revestive
29 July 2016 - CADTH has recommended that Shire's teduglutide (Revestive) be reimbursed in Canada.
The Canadian Drug Expert Committee has recommended that teduglutide be reimbursed for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support and who meet certain criteria.
The recommendation is conditional on a substantial price reduction.
